2019
DOI: 10.1001/jamaoncol.2018.4616
| View full text |Cite|
|
Sign up to set email alerts
|

Abstract: Key Points Question Can the diagnosis of benign disease or cancer in thyroid nodules with indeterminate cytology be established by molecular testing instead of diagnostic surgery? Findings This prospective, blinded, multicenter cohort study of a multigene genomic classifier (ThyroSeq v3) test included 257 indeterminate cytology thyroid nodules with informative test results. It demonstrated a high sensitivity (94%) and reasonably high specificity (82%), with… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

19
319
5
6

Year Published

2019
2019
2023
2023

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 318 publications
(349 citation statements)
references
References 48 publications
19
319
5
6
Order By: Relevance
“…It demonstrated that the NPV of the ThyroSeq GC is expected to remain at ≥95% in populations with a disease prevalence of up to 40% for thyroid nodules classified as AUS/FLUS and up to 60% for nodules classified as SFN/FN. 20 This is well within the range of cancer/NIFTP prevalence expected in these TBSRTC diagnostic categories. 7,9,24 Therefore, a ThyroSeq V3 GC-negative result may prevent diagnostic surgery for patients with thyroid nodules diagnosed as either AUS/FLUS or SFN/FN in most clinical settings.…”
Section: Clinical Validation Of the Thyroseq V3 Gcsupporting
confidence: 73%
See 4 more Smart Citations
“…It demonstrated that the NPV of the ThyroSeq GC is expected to remain at ≥95% in populations with a disease prevalence of up to 40% for thyroid nodules classified as AUS/FLUS and up to 60% for nodules classified as SFN/FN. 20 This is well within the range of cancer/NIFTP prevalence expected in these TBSRTC diagnostic categories. 7,9,24 Therefore, a ThyroSeq V3 GC-negative result may prevent diagnostic surgery for patients with thyroid nodules diagnosed as either AUS/FLUS or SFN/FN in most clinical settings.…”
Section: Clinical Validation Of the Thyroseq V3 Gcsupporting
confidence: 73%
“…The ThyroSeq V3 GC demonstrated a fairly high PPV of 66% in thyroid FNA specimens diagnosed as AUS/FLUS and SFN/FN. As shown in Table 2, 20 the test correctly identified all Hurthle cell (oncocytic) carcinomas and NIFTP nodules as positive. There were 34 test-positive samples diagnosed by pathology as benign after surgery.…”
Section: Clinical Validation Of the Thyroseq V3 Gcmentioning
confidence: 85%
See 3 more Smart Citations